Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Items 101–200 of 746
Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform 1 Inhibitors
Amata, E., Marrazzo, A., Dichiara, M., Modica, M. N., Salerno, L., Prezzavento, O., Nastasi, G., Rescifina, A., Romeo, G., & Pittalà, V. (2017) · ChemMedChem · doi:10.1002/cmdc.201700321 · Cited by 37
Glucocorticoid receptor modulators decrease alcohol self-administration in male rats
McGinn, M. A., Tunstall, B. J., Schlosburg, J. E., Gregory-Flores, A., George, O., de Guglielmo, G., Mason, B. J., Hunt, H. J., Koob, G. F., & Vendruscolo, L. F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108510 · Cited by 35
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Kuemper, S., Cairns, A. G., Birchall, K., Yao, Z., & Large, J. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1370509 · Cited by 35
Girst, G., Ötvös, S. B., Fülöp, F., Balogh, G. T., & Hunyadi, A. (2021) · Molecules · doi:10.3390/molecules26123542 · Cited by 35
Tang, H., Jensen, K., Houang, E. M., McRobb, F. M., Bhat, S., Svensson, M., Bochevarov, A. D., Day, T., Dahlgren, M. K., Bell, J. A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00118 · Cited by 35
Bung, N., Krishnan, S. R., & Roy, A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00462 · Cited by 35
Richardson, R. S., Sulima, A., Rice, K. C., Kucharczk, J. A., Janda, K. D., Nisbett, K. E., Koob, G. F., Vendruscolo, L. F., & Leggio, L. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109643 · Cited by 35
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy
Mezeiová, E., Korábečný, J., Šepsová, V., Hrabinová, M., Jošt, P., Múčková, Ľ., Kucera, T., Doležal, R., Misík, J., Špilovská, K., et al. (2017) · Molecules · doi:10.3390/molecules22081265 · Cited by 35
“4); (iii) molecular weight (MW); (iv) topological polar surface area (TPSA); (v) number of hydrogen bond donors (HBD); and (vi) pKa value for the most basic center in the molecule (CpKa) [55].”
BackgroundMethodUrbina, F., Zorn, K. M., Brunner, D., & Ekins, S. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00265 · Cited by 34
Practical approaches to evaluating and optimizing brain exposure in early drug discovery
Freeman, B. B., Yang, L., & Ranković, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111643 · Cited by 34
Elend, L., Jacobsen, L., Cofala, T., Prellberg, J., Teusch, T., Krämer, O., & Solov’yov, I. A. (2022) · Molecules · doi:10.3390/molecules27134020 · Cited by 33
Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity
Johansson, P., Kaspersson, K., Gurrell, I. K., Bäck, E., Eketjäll, S., Scott, C. W., Cebers, G., Thorne, P. V., McKenzie, M. J., Beaton, H. G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01716 · Cited by 33
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Holmqvist, A., Kocatürk, N. M., Duncan, C., Riley, J., Baginski, S. R., Marsh, G. P., Cresser-Brown, J. O., Maple, H. J., Juvonen, K. R., Sathe, G. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63928-8 · Cited by 32
Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
Ntafoulis, I., Koolen, S. L. W., Leenstra, S., & Lamfers, M. L. M. (2022) · Cancers · doi:10.3390/cancers14153705 · Cited by 32
“based this drug discovery method on an algorithm by which molecules can be characterized based on their physicochemical properties to predict CNS penetration [40].”
BackgroundMethodInfluentialSaffari, A., Brechmann, B., Böger, C., Saber, W. A., Jumo, H., Whye, D., Wood, D., Wahlster, L., Alecu, J. E., Ziegler, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44264-1 · Cited by 32
Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
Savonije, K., Meek, A. R., & Weaver, D. F. (2023) · Brain Sciences · doi:10.3390/brainsci13060852 · Cited by 31
“This may render the majority of existing drug candidates unsuitable for CNS-targeted therapies, although tools exist for rapidly screening drug candidates, such as the BBB Score [41] and the Central Nervous System Multiparameter Optimization calculator [42].”
BackgroundStructural attributes influencing unbound tissue distribution
Orozco, C. C., Atkinson, K. A., Ryu, S., Chang, G., Keefer, C. E., Lin, J., Riccardi, K. A., Mongillo, R., Tess, D. A., Filipski, K. J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111813 · Cited by 31
Bonifazi, A., Battiti, F. O., Sanchez, J., Zaidi, S. A., Bow, E. W., Makarova, M., Cao, J., Shaik, A. B., Sulima, A., Rice, K. C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00611 · Cited by 31
Today’s drug discovery and the shadow of the rule of 5
Young, R. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2228199 · Cited by 30
“This metric is evidently the least violated of the Ro5 guidelines in most analyses [14,26], which often note that <2 is a more realistic number in oral drugs, in particular if penetration of the blood brain barrier is required [48].”
BackgroundCentral Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30
“, through the use of the MultiParameter Optimisation (MPO) guidelines [10].”
MethodGampa, G., Kim, M., Cook-Rostie, N., Laramy, J. K., Sarkaria, J. N., Paradiso, L. J., DePalatis, L., & Elmquist, W. F. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079194 · Cited by 30
“Such observations have been reported for other targeted agents such as lorlatinib [anaplastic lymphoma kinase (ALK) inhibitor] and AZD3759 [epidermal growth factor receptor (EGFR) inhibitor] (Johnson et al., 2014; Zeng et al., 2015).”
BackgroundEnrique, A., Ianni, M. E. D., Goicoechea, S., Lazarowski, A., Valle-Dorado, M. G., Costa, J. J. L., Rocha, L., Girardi, E., & Talevi, A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.106451 · Cited by 30
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 29
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig.”
InfluentialNo Denying It: Medicinal Chemistry Training Is in Big Trouble
Rafferty, M. F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00741 · Cited by 29
Kumar, D. M., & Talwar, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1616144 · Cited by 29
Small molecule targeting of RNA structures in neurological disorders
Angelbello, A. J., Chen, J. L., & Disney, M. D. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14051 · Cited by 28
Chrienová, Ž., Rysanek, D., Olekšák, P., Stary, D., Bajda, M., Reiniš, M., Mikyšková, R., Novotny, O., Andrýs, R., Skarka, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1048260 · Cited by 28
Thakur, A., Sharma, B., Parashar, A., Sharma, V., Kumar, A., & Mehta, V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192805 · Cited by 28
“The value of CNS MPO score ranges from 0 to 6 for a molecule and the predicted score for a molecule to have an excellent CNS permeability is considered to be � 4, however, the CNS MPO above 3 is considered acceptable to have good CNS permeability (Wager et al., 2016).”
BackgroundKinase Targets in Cns Drug Discovery
Gunosewoyo, H., Yu, L.-F., Munoz, L., & Kassiou, M. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0214 · Cited by 28
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Wager, T. T., Galatsis, P., Chandrasekaran, R. Y., Butler, T. W., Li, J., Zhang, L., Mente, S., Subramanyam, C., Liu, S., Doran, A. C., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00155 · Cited by 28
Self-citationLeveraging chromatography based physicochemical properties for efficient drug design
Goetz, G. H., & Shalaeva, M. Y. (2018) · ADMET & DMPK · doi:10.5599/admet.529 · Cited by 28
“It demonstrated a good correlation between a high score (> 4 out of a possible max of 6) and good in vitro ADME properties [12,78].”
BackgroundSynthesis and evaluation of NLRP3-inhibitory sulfonylurea [11C]MCC950 in healthy animals
Hill, J. R., Shao, X., Massey, N. L., Stauff, J., Sherman, P. S., Robertson, A. A. B., & Scott, P. J. H. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127186 · Cited by 28
Gao, L. T., Shaabani, S., Romero, A. R., Xu, R., Ahmadianmoghaddam, M., & Dömling, A. S. S. (2023) · Green Chemistry · doi:10.1039/d2gc04312b · Cited by 27
Pagare, P. P., Li, M., Zheng, Y., Kulkarni, A. S., Obeng, S., Huang, B., Ruiz, C., Gillespie, J. C., Mendez, R. E., Stevens, D. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00087 · Cited by 26
In Silico Approaches for Addressing Challenges in CNS Radiopharmaceutical Design
Jackson, I. M., Webb, E., Scott, P. J. H., & James, M. L. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00269 · Cited by 26
Non-invasive Imaging of Antisense Oligonucleotides in the Brain via In Vivo Click Chemistry
Cook, B. E., Archbold, J., Nasr, K., Girmay, S., Goldstein, S. I., Li, P., Dandapani, S., Genung, N. E., Tang, S.-P., McClusky, S., et al. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01744-y · Cited by 26
Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents
Ahmed, S. H. H., Gonda, T., Agbadua, O. G., Girst, G., Berkecz, R., Kúsz, N., Tsai, M.-C., Wu, C., Balogh, G. T., & Hunyadi, A. (2023) · Antioxidants · doi:10.3390/antiox12030744 · Cited by 26
“[52]; and (b) experimentally, through determination of kinetic solubility and”
BackgroundInfluentialA New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
Kopp, K. O., Greer, M. E., Glotfelty, E. J., Hsueh, S., Tweedie, D., Kim, D. S., Reale, M., Vargesson, N., & Greig, N. H. (2023) · Biomolecules · doi:10.3390/biom13050747 · Cited by 26
“…degrade the neosubstrates, whose degradation is associated with teratogenic/anticancer effects (SALL4, Ikaros, 3,6′-DP binds cereblon, but it does not degrade the neosubstrates, whose degradation is associated with teratogenic/anticancer effects (SALL4, Ikaros, [ [ [ CLog CLog CLog BBB BBB Table 1.”
Hartz, R. A., Ahuja, V. T., Luo, G., Chen, L., Sivaprakasam, P., Xiao, H., Krause, C., Clarke, W., Xu, S., Tokarski, J. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00364 · Cited by 26
Tzvetkov, N. T., Stammler, H., Hristova, S., Atanasov, A. G., & Antonov, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.009 · Cited by 26
Ly, C., Shimizu, A., Vargas, M. V., Duim, W. C., Wender, P. A., & Olson, D. E. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00175 · Cited by 26
Komatović, K., Matošević, A., Terzić, N., Žunec, S., Šegan, S. B., Zlatović, M. V., Maraković, N., Bosak, A., & Opsenica, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061305 · Cited by 26
Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)
Genung, N. E., & Guckian, K. M. (2017) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2016.11.004 · Cited by 27
Le, K., Soth, M., Cross, J. B., Liu, G., Ray, W. J., Ma, J., Goodwani, S., Acton, P. J., Buggia-Prévot, V., Akkermans, O., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00788 · Cited by 25
Non-animal models for blood–brain barrier permeability evaluation of drug-like compounds
Dehnbostel, F. O., Dixit, V. A., Preißner, R., & Banerjee, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-59734-9 · Cited by 25
“Several computational approaches have been developed and applied to predict favourable CNS drug properties, aiding the selection and optimisation of lead compounds 10 .”
MethodGou, R., Yang, J., Guo, M., Chen, Y., & Xue, W. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00504 · Cited by 25
Kocsis, A. E., Kucsápszky, N., Santa-Maria, A. R., Hunyadi, A., Deli, M. A., & Walter, F. R. (2025) · Nutrients · doi:10.3390/nu17050766 · Cited by 25
Wager, T. T., Chappie, T. A., Horton, D. B., Chandrasekaran, R. Y., Samas, B., Dunn-Sims, E. R., Hsu, C. C., Nawreen, N., Vanase-Frawley, M. A., O’Connor, R. E., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00297 · Cited by 25
Self-citationUgi Multicomponent Reaction Based Synthesis of Medium-Sized Rings
Abdelraheem, E. M. M., Madhavachary, R., Rossetti, A., Kurpiewska, K., Kalinowska‐Tłuścik, J., Shaabani, S., & Dömling, A. S. S. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b03094 · Cited by 25
Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities
Cousins, R. P. C. (2022) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2022.05.001 · Cited by 24
Socała, K., Jakubiec, M., Abram, M., Mlost, J., Starowicz, K., Kamiński, R. M., Ciepiela, K., Andres‐Mach, M., Zagaja, M. P., Metcalf, C. S., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102634 · Cited by 24
“Table 4 and Table 5 show compounds with favorable in vivo CNS exposure or with satisfying in silico parameters determined by central nervous system multiparameter optimization (CNS MPO) approach (Wager et al., 2016) for compounds lacking in vivo pharmacokinetic results, respectively.”
BackgroundDiosmin induces caspase-dependent apoptosis in human glioblastoma cells
SOARES, J. M., de Faria, B. M., Ascari, L. M., Alves‐Leon, S. V., de Souza, J. M., Soares, A. G., Cordeiro, Y., & Romão, L. F. (2019) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201920191031 · Cited by 24
“Furthermore, the brain penetration of drugs is facilitated in glioblastoma, since the high rate of parenchyma infiltration causes vascular fragility and weakens the BBB (dubois et al. 2014).”
BackgroundInfluentialLeucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016)
Galatsis, P. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280464 · Cited by 24
“count, and pKa), and the CNS multi-parameter optimization (MPO) score provides a holistic measure of assessing these parameters when describing CNS drug-like space [60,61].”
BackgroundLuo, Z., Rosenberg, A. J., Liu, H., Han, J., & Tu, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.035 · Cited by 24
Scarpellini, C., Klejborowska, G., Lanthier, C., Toye, A., Musiałek, K., San, E. V., Walravens, M., Berg, M., Hassannia, B., der Veken, P. V., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03149 · Cited by 23
Wang, S., Song, H., Yin, C., & Huo, F. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216940 · Cited by 23
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac126.84718491 · Cited by 23
“As a general rule, good oral bioavailability is associated with values of 0 < logP < 3 (good permeability and solubility) since very high values of logP result in low aqueous solubility, while very low values make it difficult to penetrate the lipid bilayer of cell membranes [23,26].”
BackgroundInfluentialDevelopment of copper-catalyzed deaminative esterification using high-throughput experimentation
Shen, Y., Mahjour, B. A., & Cernak, T. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00698-0 · Cited by 23
Graham, T. J. A., Lindberg, A., Tong, J., Stehouwer, J. S., Vasdev, N., Mach, R. H., & Mathis, C. A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00775 · Cited by 23
Szewczyk, S. M., Verma, I., Edwards, J. T., Weiss, D. R., & Chekler, E. L. P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01872 · Cited by 23
Engers, J. L., Childress, E. S., Long, M. F., Capstick, R. A., Luscombe, V. B., Cho, H. P., Dickerson, J. W., Rook, J. M., Blobaum, A. L., Niswender, C. M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00261 · Cited by 23
Tzvetkov, N. T., Stammler, H., Georgieva, M. G., Russo, D., Faraone, I., Balacheva, A. A., Hristova, S., Atanasov, A. G., Milella, L., Antonov, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.041 · Cited by 23
Rui, M., Rossino, G., Coniglio, S., Monteleone, S., Scuteri, A., Malacrida, A., Rossi, D., Catenacci, L., Sorrenti, M., Paolillo, M., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.010 · Cited by 23
Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents
Corfu, A. I., Santarém, N., Luelmo, S., Mazza, G., Greco, A., Altomare, A., Ferrario, G., Nasta, G., Keminer, O., Aldini, G., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00181 · Cited by 22
Gogarnoiu, E. S., Vogt, C. D., Sanchez, J., Bonifazi, A., Saab, E., Shaik, A. B., Soler‐Cedeño, O., Bi, G., Klein, B., Xi, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01624 · Cited by 22
Wu, X., Shen, Y., Tan, S., Jiang, X., Chen, Z., Yu, Q., Chen, H., Zhuang, Y., Zeng, H., Fu, X., et al. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115415 · Cited by 22
Basagni, F., Ortega, J. A., Bertozzi, S. M., Armirotti, A., Summa, M., Bertorelli, R., Bartolini, M., Mellor, I. R., Bedeschi, M., Bottegoni, G., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115803 · Cited by 22
Pike, K. G., Hunt, T. A., Barlaam, B. C., Benstead, D., Cadogan, E. B., Chen, K., Cook, C., Colclough, N., Deng, C., Durant, S. T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02277 · Cited by 22
Chen, Y., Wu, B., Hao, Y., Liu, Y., Zhang, Z., Tian, C., Ning, X., Guo, Y. Q., Liu, J., & Wang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.044 · Cited by 22
Lacivita, E., Niso, M., Mastromarino, M., Silva, A., Resch, C., Zeug, A., Loza, M. I., Castro, M., Ponimaskin, E. G., & Leopoldo, M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00647 · Cited by 22
Cores, Á., Carmona-Zafra, N., Martín-Cámara, O., Sánchez, J. D., Duarte, P., Villacampa, M., Bermejo‐Bescós, P., Martín‐Aragón, S., Leon, R. M., & Menéndez, J. C. (2021) · Antioxidants · doi:10.3390/antiox11010028 · Cited by 22
“0, in comparison to 60% of the Pfizer CNS candidates [30].”
ResultFluoroalkylation of Dextromethorphan Improves CNS Exposure and Metabolic Stability
Sorrentino, J. P., & Altman, R. A. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00055 · Cited by 22
Predictive ADMET study of rhodanine-3-acetic acid chalcone derivatives
da Rocha, M. N., Marinho, M. M., Teixeira, A. M. R., Marinho, E. S., & dos Santos, H. S. (2022) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2022.100535 · Cited by 22
Matošević, A., Knežević, A., Zandona, A., Maraković, N., Kovarik, Z., & Bosak, A. (2022) · Pharmaceuticals · doi:10.3390/ph15101220 · Cited by 21
Horne, R. I., Murtada, M. H., Huo, D., Brotzakis, Z. F., Gregory, R. C., Possenti, A., Chia, S., & Vendruscolo, M. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c01303 · Cited by 23
Bonifazi, A., Saab, E., Sanchez, J., Nazarova, A. L., Zaidi, S. A., Jahan, K., Katritch, V., Canals, M., Lane, J. R., & Newman, A. H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00417 · Cited by 21
Balanced Permeability Index: A Multiparameter Index for Improved In Vitro Permeability
Weiss, D. R., Baylon, J. L., Evans, E. D., Paiva, A., Everlof, G. G., Cutrone, J., & Broccatelli, F. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00542 · Cited by 21
Butler, C. R., Popiolek, M., McAllister, L. A., LaChapelle, E., Kramer, M., Beck, E. M., Mente, S., Brodney, M. A., Brown, M. F., Gilbert, A. M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00293 · Cited by 21
Obende, S. O., Ochieng, C. O., Shikanga, E. A., Cruz, J. N., Santos, C. B. R., & Kimani, N. M. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.06.031 · Cited by 21
Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery
Mayol-Llinàs, J., Farnaby, W., & Nelson, A. S. (2017) · Chemical Communications · doi:10.1039/c7cc06078e · Cited by 21
Oliveira, S. R., Dionísio, P. A., Gaspar, M. M., Ferreira, M. B. T., Rodrigues, C. A. B., Gonçalves‐Pereira, R., Estevão, M. S., Perry, M. D. J., Moreira, R., Afonso, C. A. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105289 · Cited by 21
Blain, J., Bursavich, M. G., Freeman, E. A., Hrdlicka, L., Hodgdon, H., Chen, T., Costa, D., Harrison, B. A., Kapadnis, S., Murphy, D. A., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0199-5 · Cited by 21
Fu, H., Tang, W., Chen, Z., Belov, V., Zhang, G., Shao, T., Zhang, X., Yu, Q., Rong, J., Deng, X., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00591 · Cited by 21
Silva, J., Rocha, J. E., Xavier, J. D. C., de Freitas, T. S., Coutinho, H. D. M., Bandeira, P. N., de Oliveira, M. R., da Rocha, M. N., Marinho, E. M., Monteiro, N. D. K. V., et al. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105664 · Cited by 20
Roecker, A. J., Schirripa, K. M., Loughran, H. M., Tong, L., Liang, T., Fillgrove, K. L., Kuo, Y., Bleasby, K., Collier, H., Altman, M. D., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00441 · Cited by 21
da Silva, C. P. M., das Neves, G. M., von Poser, G. L., Eifler-Lima, V. L., & Rates, S. M. K. (2023) · Medicinal Chemistry · doi:10.2174/1573406419666230601092358 · Cited by 21
Xu, Y., Xu, Y., Biby, S., Kaur, B., Liu, Y., Bagdasarian, F. A., Wey, H., Tanzi, R. E., Zhang, C. M., Wang, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01782 · Cited by 20
Kusaczuk, M., Ambel, E. T., Martín-Cabrera, P., Lorente, M., Salvador, N., Mikłosz, A., Chabowski, A., Velasco, G., & Naumowicz, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910740 · Cited by 20
Neuropharmacology: Oxime antidotes for organophosphate pesticide and nerve agent poisoning
Zorbaz, T. (2020) · Periodicum Biologorum · doi:10.18054/pb.v121-122i1-2.10623 · Cited by 20
de Oliveira, V. M., da Rocha, M. N., Magalhães, E. P., Mendes, F. R. D. S., Marinho, M. M., de Menezes, R. R. P. P. B., Sampaio, T. L., dos Santos, H. S., Martins, A. M. C., & Marinho, E. S. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00334-z · Cited by 20
Thurairatnam, S., Lim, S., Barker, R. H., Choi-Sledeski, Y. M., Hirth, B. H., Jiang, J., Macor, J. E., Makino, E., Maniar, S., Musick, K., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00120 · Cited by 20
Feng, H., Gao, K., Chen, D., Shen, L., Robison, A. J., Ellsworth, E. L., & Wei, G. (2022) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c00002 · Cited by 19
“ADMET (absorption, distribution, metabolism, excretion, and toxicity) includes a diversity of attributes associated with the pharmacokinetic attributes of a compound, and is an important factor in drug design [72].”
BackgroundMiconazole-like Scaffold is a Promising Lead for Naegleria fowleri-Specific CYP51 Inhibitors
Sharma, V., Madia, V. N., Tudino, V., Nguyen, J. V., Debnath, A., Messore, A., Ialongo, D., Patacchini, E., Palenca, I., Franzin, S. B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01898 · Cited by 19
CNS delivery of targeted protein degraders
Agarwal, P., Reid, D. L., & Amiji, M. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.057 · Cited by 19
Doost, M. E., Hong, J., Broatch, J., Applegate, M. T., Wagner, C. E., Marshall, P. A., & Jurutka, P. W. (2024) · Cells · doi:10.3390/cells13221878 · Cited by 19
“The CNS MPO (Central Nervous System Multiparam-eter Optimization) Score was calculated using [38].”
Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)
Koester, D. C., Marx, V. M., Williams, S., Jiřiček, J., Dauphinais, M., René, O., Miller, S. L., Zhang, L., Patra, D., Chen, Y., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00791 · Cited by 19
El‐Mansy, M. F., Reidl, C. T., Rahaman, M., Özdinler, P. H., & Silverman, R. B. (2023) · Medicinal Research Reviews · doi:10.1002/med.21974 · Cited by 18
“75 Several compounds had high Δ T m values and desirable MPO scores to be considered as potential candidates.”
BackgroundMethodInfluentialChen, J., Garcia, E. J., Merritt, C. R., Zamora, J. C., Bolinger, A. A., Pazdrak, K., Stafford, S. J., Mifflin, R. C., Wold, E. A., Wild, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00908 · Cited by 18
Tautermann, C. S., Borghardt, J. M., Pfau, R., Zentgraf, M., Weskamp, N., & Sauer, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103758 · Cited by 18
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.